Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-20S in Relapsed/Refractory CD20+ Non-Hodgkin's Lymphoma
NCT04176913Phase 1Terminated
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-20S in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Dose Limiting Toxicity, Adverse Events and 2 more. Started Dec 2020; status: terminated.
02
Drugs
LUCAR-20S
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04176913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176913.